TP53 and breast cancer: To experimentally evaluate our in silico predictions, we introduced microRNA inhibitors in a modified breast cancer cell line MCF7, and performed time-lapse microscopy tracking single-cell p53 dynamics under induced DNA double-stranded breaks.